Human papillomavirus and genital cancer

Indian Journal of Dermatology, Venereology and Leprology

Volumn 75, Issue 3, 2009, Pages 236-244

  Rapose, Alwyn ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Anal cancer; Cervical cancer; HPV vaccine; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ANUS INTERCOURSE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CIGARETTE SMOKING; CIRCUMCISION; CLINICAL TRIAL; CONDOM; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DISEASE DURATION; DRUG MECHANISM; GENITAL TRACT CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; INFECTION RISK; MORBIDITY; MOUTH INFECTION; PAPANICOLAOU TEST; PATHOGENESIS; PENIS CANCER; PREVALENCE; REVIEW; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ALPHAPAPILLOMAVIRUS; CONDYLOMATA ACUMINATA; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 67249108632     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.48429     Document Type: Review

References (66)

1. Antonsson A, Erfurt C, Hazard K, Holmgren V, Simon M, Kataoka A, et al. Prevalence and type spectrum of Human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol 2003;84:1881-6.
2. Goon P, Sonnex C, Jani P, Stanley M, Sudhoff H. Recurrent respiratory papillomatosis: An overview of current thinking and treatment. Eur Arch Otorhinolaryngol 2008;265:147-51.
3. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-80.
4. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
5. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991;67:547-56.
6. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
7. Pande S, Jain N, Prusty BK, Bhambahani S, Gupta S, Sharma R, et al. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J Clin Microbiol 2008;46:1060-6.
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against Human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
9. Stark A, Gregoire L, Pilarski R, Zarbo A, Gaba A, Lancaster WD. Human papillomavirus, cervical cancer and women's knowledge. Cancer Detect Prev 2008;32:15-22.
10. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the U.S. know about Human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev 2007;16:288-94.
11. Goldsmith MR, Bankhead CR, Kehoe ST, Marsh G, Austoker J. Information and cervical screening: A qualitative study of women's awareness, understanding and information needs about HPV. J Med Screen 2007;14:29-33.
12. Giles M, Garland S. A study of women's knowledge regarding Human papillomavirus infection, cervical cancer and Human papillomavirus vaccines. Aust N Z J Obstet Gynaecol 2006;46:311-5.
13. Jain N, Irwin KL, Montano D, Kasprzyk D, Carlin L, Freeman C, et al. Family physicians' knowledge of genital Human papillomavirus (HPV) infection and HPV-related conditions, United States, 2004. Fam Med 2006;38:483-9.
14. Cancer Facts and Figures. American Cancer Society. Available from: http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf. [last accessed on 2008 Jul 5].
15. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvar cancer: Changes in localization and age of onset. Gynecol Oncol 2008;109:340-5.
16. Patro BK, Nongkynrih B. Review of screening and preventive strategies for cervical cancer in India. Indian J Public Health 2007;51:216-21.
17. Campisi G, Panzarella V, Termine N, Giovannelli L. Comment on "Human papillomavirus in the oral mucosa of women with genital Human papillomavirus lesions" [Eur. J. Obstet. Gynecol. Reprod. Biol. 126 (2006) 104-106]. Eur J Obstet Gynecol Reprod Biol 2007;130:142-3; author reply 143.
18. Bhatla N, Lal N, Bao Y P, Ng T, Qiao YL. A meta-analysis of Human papillomavirus type-distribution in women from South Asia: Implications for vaccination. Vaccine 2008;26:2811-7.
19. Bhatla N, Dar L, Rajkumar PA, Kumar P, Pati SK, Kriplani A, et al. Human papillomavirus-type distribution in women with and without cervical neoplasia in North India. Int J Gynecol Pathol 2008;27:426-30.
20. Insinga R P, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical Human papillomavirus 6, 11, 16, and 18 infections in young women: An evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.
21. Winer RL, Lee SK, Hughes J P, Adam DE, Kiviat NB, Koutsky LA. Genital Human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
22. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of clearance of Human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486-94.
23. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, et al. Time to clearance of Human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006;119:1623-9.
24. Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC, et al. Prevalence of Human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006;194:428-34.
25. Fakhry C, D'Souza G, Sugar E, Weber K, Goshu E, Minkoff H, et al. Relationship between prevalent oral and cervical Human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 2006;44:4479-85.
26. Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL. Cervical and oral Human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol 2008;80:953-9.
27. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific Human papillomavirus infections: The Young Women's Health Study. J Infect Dis 2002;186:462-9.
28. Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am 2004; 13:263-75.
29. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Ning L, et al. Acquisition of anal Human papillomavirus (HPV) infection in women: The Hawaii HPV Cohort study. J Infect Dis 2008;197:957-66.
30. Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: Prevalence and associated factors. AIDS 2007;21:1457-65.
31. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93:843-9.
32. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal Human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003;138:453-9.
33. Vaccarella S, Lazcano-Ponce E, Castro-Garduno JA, Cruz-Valdez A, Diaz V, Schiavon R, et al. Prevalence and determinants of Human papillomavirus infection in men attending vasectomy clinics in Mexico. Int J Cancer 2006;119:1934-9.
34. Partridge JM, Hughes J P, Feng Q, Winer RL, Weaver BA, Xi L F, et al. Genital Human papillomavirus infection in men: Incidence and risk factors in a cohort of university students. J Infect Dis 2007;196:1128-36.
35. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Kornegay JR, et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2003;187:1064-70.
36. Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ. Risk factors for genital HPV DNA in men resemble those found in women: A study of male attendees at a Danish STD clinic. Sex Transm Infect 2002;78:215-8.
37. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile Human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 2004;31:601-7.
38. Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee SK, Meyer C, et al. Evaluation of genital sites and sampling techniques for detection of Human papillomavirus DNA in men. J Infect Dis 2004;189:677-85.
39. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-76.
40. Prowse DM, Ktori EN, Chandrasekaran D, Prapa A, Baithun S. Human papillomavirus-associated increase in p16INK4A expression in penile lichen sclerosus and squamous cell carcinoma. Br J Dermatol 2008;158:261-5.
41. Pascual A, Pariente M, Godinez JM, Sanchez-Prieto R, Atienzar M, Segura M, et al. High prevalence of Human papillomavirus 16 in penile carcinoma. Histol Histopathol 2007;22:177-83.
42. Nicolau SM, Camargo CG, Stavale JN, Castelo A, Dores GB, Lorincz A, et al. Human papillomavirus DNA detection in male sexual partners of women with genital Human papillomavirus infection. Urology 2005;65:251-5.
43. Sirera G, Videla S, Pinol M, Canadas M P, Llatjos M, Ballesteros AL, et al. High prevalence of Human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS 2006;20:1201-4.
44. Nyitray A, Nielson CM, Harris RB, Flores R, Abrahamsen M, Dunne E F, et al. Prevalence of and risk factors for anal Human papillomavirus infection in heterosexual men. J Infect Dis 2008;197:1676-84.
45. Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, et al. The optimal anatomic sites for sampling heterosexual men for Human papillomavirus (HPV) detection: The HPV detection in men study. J Infect Dis 2007;196:1146-52.
46. McCloskey JC, Metcalf C, French MA, Flexman J P, Burke V, Beilin LJ. The frequency of high-grade intraepithelial neoplasia in anal/perianal warts is higher than previously recognized. Int J STD AIDS 2007;18:538-42.
47. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta- analysis. Sex Transm Dis 2002;29:725-35.
48. Franceschi S, Castellsague X, Dal Maso L, Smith JS, Plummer M, Ngelangel C, et al. Prevalence and determinants of Human papillomavirus genital infection in men. Br J Cancer 2002;86:705-11.
49. Genuis SJ, Genuis SK. Managing the sexually transmitted disease pandemic: A time for reevaluation. Am J Obstet Gynecol 2004;191:1103-12.
50. Crosby R, Diclemente RJ, Yarber WL, Snow G, Troutman A. An event-specific analysis of condom breakage among African American men at risk of HIV acquisition. Sex Transm Dis 2008;35:174-7.
51. Yarber WL, Graham CA, Sanders SA, Crosby RA. Correlates of condom breakage and slippage among university undergraduates. Int J STD AIDS 2004;15:467-72.
52. Richters J, Knox S, Crawford J, Kippax S. Condom use and 'withdrawal': Exploring gay men's practice of anal intercourse. Int J STD AIDS 2000;11:96-104.
53. Allergy NIo. Scientific evidence on condom effectiveness for sexually transmitted disease (STD) prevention. [cited on 2001 Jul 20]. Available from: http://www.niaid.nih.gov/research/topics/ STI/pdf/condomreport.pdf. [last accessed on 2008 May 12].
54. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744-54.
55. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32:S59-66.
56. Giraldo P, Gonçalves AK, Pereira SA, Barros-Mazon S, Gondo ML, Witkin SS. Human papillomavirus in the oral mucosa of women with genital Human papillomavirus lesions. Eur J Obstet Gynecol Reprod Biol 2006;126:104-6.
57. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008;109:S15-21.
58. Villa LL, Costa RL, Petta CA, Andrade R P, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent Human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95: 1459-66.
59. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade R P, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent Human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-9.
60. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic Human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
61. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against Human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
62. FUTURE II Study Group. Prophylactic Efficacy of a quadrivalent Human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196:1438-46.
63. Krul EJ, Van De Vijver MJ, Schuuring E, Van Kanten RW, Peters AA, Fleuren GJ. Human papillomavirus in malignant cervical lesions in Surinam: A high-risk country, compared to the Netherlands, a low-risk country. Int J Gynecol Cancer 1999;9:206-11.
64. Antonishyn NA, Horsman GB, Kelln RA, Saggar J, Severini A. The impact of the distribution of Human papillomavirus types and associated high-risk lesions in a colposcopy population for monitoring vaccine efficacy. Arch Pathol Lab Med 2008;132: 54-60.
65. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, Chang Chien CC. High prevalence of genital Human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006;101:40-5.
66. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of Human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007;298: 743-53.